INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences to Present at Upcoming Investor Conferences

May 26, 2020

DURHAM, N.C., May 26, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform today announced its participation in the following upcoming investor...

Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update

May 15, 2020

Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in 2020; Phase 1/2a Trial of PBCAR269A in Patients with Multiple Myeloma Expected to Begin in 2020 Expect to Select...

Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020

May 7, 2020

DURHAM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® genome editing platform, announced today that it will report financial results for the first...

Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

April 28, 2020

DURHAM, N.C. , April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present...

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources

April 15, 2020

DURHAM, N.C., April 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® genome editing platform, today announced that Dora Alvarado has joined the leadership team...

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

April 7, 2020

PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic FDA has authorized Precision to begin dosing with PBCAR20A at Dose Level 2 DURHAM, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc....

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

March 11, 2020

DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

March 10, 2020

-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical activity, CAR T cell expansion and persistence- -Received FDA IND clearance and Orphan Drug...

Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences

February 21, 2020

DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, announced today that it will publish financial results for the fiscal year and...

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

January 13, 2020

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma- -First...

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
SEC Filings
Investor FAQs
Corporate Deck
2019 Annual Report

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal